{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:51:59Z","timestamp":1792889519864,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cllc.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T19:53:07Z","timestamp":1686858787000},"page":"e254-e258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Design and Rationale for a Phase II\/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Shen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-0761","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2023.06.009_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: Cancer J Clin"},{"issue":"8","key":"10.1016\/j.cllc.2023.06.009_bib0002","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.mayocp.2019.01.034","article-title":"Current diagnosis and management of small-cell lung cancer","volume":"94","author":"Wang","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"23","key":"10.1016\/j.cllc.2023.06.009_bib0003","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","article-title":"Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer","volume":"22","author":"Fried","year":"2004","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2023.06.009_bib0004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10212","key":"10.1016\/j.cllc.2023.06.009_bib0005","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"23","key":"10.1016\/j.cllc.2023.06.009_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2023.06.009_bib0007","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","article-title":"Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC","volume":"15","author":"Welsh","year":"2020","journal-title":"J Thoracic Oncol: Off Public Int Assoc Study of Lung Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2023.06.009_bib0008","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.21037\/tlcr-20-608","volume":"9","author":"Zhou","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"10.1016\/j.cllc.2023.06.009_bib0009","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00262-021-03102-3","article-title":"Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial","volume":"71","author":"Gong","year":"2022","journal-title":"Cancer Immunol, Immunotherapy : CII"},{"issue":"2","key":"10.1016\/j.cllc.2023.06.009_bib0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.cllc.2023.06.009_bib0011","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.cllc.2023.06.009_bib0012","doi-asserted-by":"crossref","first-page":"S1212","DOI":"10.1016\/j.annonc.2020.08.2328","article-title":"Durvalumab (D)\u00a0+\u00a0tremelimumab (T) \u00fe platinum-etoposide (EP) in 1L ES-SCLC: characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN","volume":"31","author":"Goldman","year":"2020","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol \/ESMO"},{"issue":"2","key":"10.1016\/j.cllc.2023.06.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.cllc.2023.06.009_bib0014","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/annonc\/mdz122","article-title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial","volume":"30","author":"Tay","year":"2019","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"issue":"1","key":"10.1016\/j.cllc.2023.06.009_bib0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtho.2017.09.1951","article-title":"Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse","volume":"13","author":"Almodovar","year":"2018","journal-title":"J Thoracic Oncol: Off Public Int Assoc Study of Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2023.06.009_bib0016","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.cllc.2023.06.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e17542","article-title":"Circulating tumor DNA\u2013based detection of molecular residual disease as a biomarker for recurrence monitoring predict disease recurrence in patients with ovarian cancer","volume":"41","author":"Lv","year":"2023","journal-title":"J Clin Oncol: Off J Am SocClin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:28Z","timestamp":1761506068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423001353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1525730423001353"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.06.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and Rationale for a Phase II\/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}